Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2026Neurology Research InternationalOpen Access

Cognitive Impairment and Quality of Life in AQP4‐IgG Seropositive Neuromyelitis Optica Spectrum Disorder: A Cross‐Sectional Study in Iranian Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SRSaeed RamazanzadehFAFereshteh Ashtari

Discussion

Loading...

Member takes

Overview

Cross-sectional study examines cognitive impairment impact on quality of life in NMOSD patients, suggesting under-recognition of cognitive issues.

Key Points

  • To explore cognitive characteristics and quality of life in AQP4-IgG seropositive NMOSD patients.
  • Cross-sectional study involving 49 NMOSD patients (30 AQP4-IgG seropositive) and 43 healthy controls.
  • Used questionnaires including MSQOL-54, BDI, and HADS for assessment.
  • Cognitive function evaluated with MACFIMS.
  • 48.98% of NMOSD patients classified as cognitively impaired; 83.33% of these were AQP4-IgG seropositive.
  • Strong correlation observed between cognitive impairment and AQP4-IgG seropositivity (p < 0.05).
  • Seropositive patients performed worse on PASAT (p < 0.05) and D-KEFS (p < 0.001) tests.

Cite This Study

Ramazanzadeh et al. (2026) studied this question.

synapsesocial.com/papers/6a01724f3a9f334c282726cdhttps://doi.org/10.1155/nri/5624714
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Socioeconomic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study2024
  2. 2Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study2024 · 6 citations
  3. 3Factors associated with cognitive impairment in patients with neuromyelitis optica spectrum disorders from Mexico2025
  4. 4A.5 Investigating myelitis and rheumatologic disease overlap in the era of neuromyelitis optica spectrum disorder and MOG Antibody-associated disease2024
  5. 5Patient-reported outcomes in Chinese patients with AQP4-IgG–positive neuromyelitis optica spectrum disorder on inebilizumab therapy: a cross-sectional study2026